BA in Political Science from St. Jerome’s University (at Waterloo)
Executive Certificate in Marketing Management from the Schulich School of Business

John-Paul brings more than 25 years of experience working in the health and pharmaceutical sectors. Prior to joining PDCI, he spent more than a decade in market access leadership roles, negotiating drug reimbursement agreements for innovative pharmaceuticals in Canada. John-Paul’s experience and knowledge in market access and negotiation strategy covers an extensive scope therapeutic and business areas, including strategic insights on how to obtain and maintain product reimbursement in both public and private markets.

John-Paul has led successful reimbursement strategies and negotiated funding agreements for conventional and specialty care products across Canada. He has worked with companies on successful negotiation strategies for the reimbursement of more than 20 drug products (Drugs for Rare Diseases, Oncology and Biomarker Testing, Cardiovascular and Diabetes, Neuroscience, and Consumer Healthcare).

At PDCI, John-Paul leads the Strategic Consulting team (Pricing, Access and Data Insights) focusing on the development and implementation of market access strategies, launch planning, data analytics and insights for the reimbursement of biopharmaceuticals, including companion devices, and diagnostics in Canada.

A sought-after speaker, strategist, and thought leader, John-Paul brings a keen understanding of the inter-relationships between Canada’s public and private drug markets, and the emerging reimbursement pathways for negotiated agreements. John-Paul is an active member of the Canadian Association for Healthcare Reimbursement, and BioteCanada (BTC), serving on the latter’s Health Advisory Board and Orphan Drug Working Group.